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Stroke is a leading cause of death and disability worldwide. The elderly, in whom atrial ﬁb-
rillation (AF) is most prevalent, carry the greatest risk, undergoing more recurrent, deadlier
strokes, with bigger deﬁcits, slower recoveries, and more comorbidities. Evidence-based
data on advanced age stroke management are scarce. Age-related cerebral changes might
undermine the beneﬁt of established stroke treatments. Nevertheless, the elderly should
probably also undergo thrombolysis for ischemic stroke: they do not bleedmore, and die not
because of hemorrhage but of concomitant illnesses. Beyond natural bleeding risks, AF in
advanced age has a high embolic potential if not anticoagulated. Standard or lower intensity
warfarin anticoagulation prevents embolic stroke in the elderly with a hemorrhage risk even
lower than aspirin. In fact, adverse effects seem to occur more often with aspirin. Excess
anticoagulation hazards are prevented with lower starting doses, stricter corrections, more
frequent International Normalized Ratio monitoring, and longer adjustment intervals. Val-
idated prognostic scores such as CHADS2 help minimize bleeds. Direct inhibitors have
recently shown a beneﬁt similar to warfarin with fewer hemorrhages. Carefully tailoring
antithrombotics to this age group is therefore useful. Antihypertensives probably help 80-
plus stroke patients as well, but the risk/beneﬁt of lowering blood pressure in secondary
stroke prevention at that age is uncertain. Evidence-based data on diabetes management
and use of lipid-lowering drugs are still lacking in this age group. In summary, emerging data
suggest that stroke management should be speciﬁcally targeted to the elderly to better
prevent its devastating consequences in the population at the highest risk.
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THE CASE FOR AN ELDERLY TARGETED STROKE
MANAGEMENT
Stroke is one of the leading causes of death and the main cause of
disabilityworldwide. The stroke rate increaseswith age: beyond 55,
it doubles each successive decade, and by 2050 the 65-plus world
population will outnumber the rest (Wolf et al., 1992; Brown et al.,
1996; Chen et al., 2010). The elderly are therefore at greater cere-
brovascular risk than anyone, and stroke will probably acquire
epidemiological proportions in the near future.
Thrombolysis, anticoagulation, antihypertensive, antiplatelet,
and antilipemic agents have all been proven of beneﬁt in stroke
treatment and prevention in the population at large. However,
management strategies useful in younger adults may not be
equally effective in the elderly, who undergo age-related cere-
bral changes that might undermine that beneﬁt, or entail further
clinical risk.
Brain weight decreases 0.1–0.2% yearly between the ages of 20
and 50, and 0.3–0.5% yearly beyond 70 (Anderson et al., 1983;
Pfefferbaum et al., 1994). Leukoaraiosis, a patchy or conﬂuent
subcortical/periventricular hypointensity on CT (or high signal
intensity on MRI), occurs in up to one-third of people aged 65–
84, and in up to 44% of patients with stroke and transient ischemic
attack (TIA). It predicts gait disturbances and cognitive decline in
the very elderly, and its degree correlates with the risk of recurrent
stroke (Breteler et al., 1994; Pfefferbaumet al., 1994; deGroot et al.,
2000; Debette et al., 2007; Smith, 2010). With aging, blood brain
barrier permeability andplasma albumin ratio in the cerebrospinal
ﬂuid increase. Capillaries enlarge, elongate, and disrupt perfu-
sion. Cerebral blood ﬂow reductions diminish protein synthesis,
induce changes in intracellular pH and water content, cause gluta-
mate/lactate accumulation, impairATP synthesis, decrease neuron
excitability, and bring on electrolyte imbalance and ultimately
ischemic neuronal death (Farrall and Wardlaw, 2009).
In various “very old” populations (beyond 80 years of age),
stroke predominates in women (Rojas et al., 2007; Andersen et al.,
2010). Atrial ﬁbrillation (AF) is most prevalent in the elderly, with
up to 23.5% of associated stroke risk at 80–89 years (Wolf et al.,
1991; Fuster et al., 2001;Adams et al., 2008), and the highest hazard
ratio beyond 65 (Rodgers et al., 2004). Contrary to younger pop-
ulations, hypertension and hyperlipidemia are less signiﬁcant risk
factors in the very old (Weverling-Rijnsburger et al., 2003; Rodgers
et al., 2004; Milionis et al., 2005; Babatsikou and Zavatsanou,
2010).
Stroke in patients beyond 85 is deadlier, entails longer hospi-
tal stays, and results in bigger deﬁcits and slower recoveries that
require assistance in daily living and ultimately institutionaliza-
tion (Arboix et al., 2000). Older stroke patients have a substantially
higher risk of stroke recurrence (Johnston et al., 2000; Kaplan et al.,
2005), and comorbidities that increase disability (Hickenbottom
et al., 2002).
Old age is therefore associated with speciﬁc cerebral structural
changes, risk factors, and clinical features that may all impair
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or delay stroke recovery. Unfortunately, because very few old
patients were included in the large stroke clinical trials, reli-
able data on elderly stroke management are scarce and have
only recently started to emerge. As a result, the population most
in need of clear stroke treatment recommendations has been
neglected.
INTRAVENOUS THROMBOLYSIS
Intravenous thrombolysis with rt-PA reduces stroke disability.
However, breakthrough trials demonstrating this beneﬁt have
either excluded very elderly patients, or randomized very few (The
National Institute of Neurological Disorders, 1995; Hacke et al.,
2008). These restrictions do not seem warranted, since patients
over 80 have not shown a higher bleeding risk, both in small cohort
studies and in larger databases (Tanne et al., 2000; Berrouschot
et al., 2005; Mouradian et al., 2005; Engelter et al., 2006; Sylaja
et al., 2006; Ford et al., 2010;Mishra et al., 2010; Table 1). This may
depend on howbleeding is deﬁned (TheNational Institute of Neu-
rological Disorders, 1995; Wahlgren et al., 2007), but in any case,
elderly stroke patients do not seem to die as a consequence of hem-
orrhage or thrombolysis, but of concomitant illnesses (Schwark
and Schellinge, 2006; Alshekhlee et al., 2010). So, if the ultimate
goal is to reduce death and disability, present data suggest the
elderly should undergo thrombolysis under the same criteria as
the general population.
ATRIAL FIBRILLATION, ANTICOAGULATION, AND ANTIPLATELET
THERAPY
Atrial ﬁbrillation leads to left atrial thrombi, carries a sixfold
annual stroke risk (Wolf et al., 1991), and is most prevalent in
the elderly. An estimated 5.6 million people will have it by 2050
in the USA, of which 50% will be over 80 (Go et al., 2001). Car-
dioembolic stroke due to AF is consequently a very high risk in
this group. From several clinical trials we know that oral antico-
agulation reduces relative stroke risk by about 68% and mortality
by 33%, and hence is the best means to prevent cardioembolic
stroke in the general population (Lip and Lowe, 1996). However,
old patients, anticoagulated or not, may also be at high bleed-
ing risk, due to factors such as amyloid angiopathy (Rosand et al.,
Table 1 |Thrombolysis in general and advanced age populations.
General population Advanced age
population
THROMBOLYSIS
Symptomatic ICH
(%)
6 (The National Institute of
Neurological Disorders, 1995),
2.4 (Hacke et al., 2008), 6
(Tanne et al., 2000), 2.6
(Berrouschot et al., 2005)
3 (Tanne et al., 2000),
6 (Berrouschot et al.,
2005)
Outcome (modiﬁed
ranking scale)
OR 1.6 (95% CI 1.5–1.7) (Ford
et al., 2010)
1.4 (95% CI 1.3–1.6)
(Ford et al., 2010)
Symptomatic intracerebral hemorrhage (ICH) and outcome (The National Insti-
tute of Neurological Disorders, 1995;Tanne et al., 2000; Berrouschot et al., 2005;
Hacke et al., 2008; Ford et al., 2010).
2000), ischemiaof arterial (rather than cardioembolic)mechanism
and concomitant medication (Gorter, 1999), or brain microb-
leeds (Roob et al., 1999). Those with AF may in fact have both
the highest spontaneous ischemic stroke risk and, when anti-
coagulated, the highest bleeding risk (Warfarin versus aspirin,
1994).
Prescribing anticoagulation is therefore a critical challenge
in the elderly (Hylek et al., 2006). Beyond conventional
contraindications, such as stomach ulcer, physicians often avoid
anticoagulation in elderly patients, for fear of intracerebral hem-
orrhage, falls, and faulty compliance (with or without cognitive
decline), choosing to leave the patient at higher embolic risk as
a result (Lew and Lim, 2002; van Walraven et al., 2009). Nev-
ertheless, using conventional optimal anticoagulation intensity
(International normalized ratio, INR 2.0–3.0; The EuropeanAtrial
Fibrillation Trial Study Group, 1995; Hylek et al., 1996; Stroke
prevention in atrial ﬁbrillation III, 1996), one trial has shown the
beneﬁt of warfarin over aspirin in preventing embolic stroke in the
elderly,with a 46% relative risk reduction, and low major extracra-
nial hemorrhage rates, not signiﬁcantly different from those with
aspirin: 1.4 vs. 1.6% per year (Mant et al., 2007). With the same
standard anticoagulation intensity, a smaller trial looked at spe-
ciﬁc adverse events (death, thromboembolism, severe hemorrhage,
withdrawal from the study), which turned out to be very signiﬁ-
cantly more frequent with aspirin (33%) than with warfarin: 6%,
p = 0.002 (Rash et al., 2007; Table 2). These are sobering results,
as antiplatelet agents are not felt to be dangerous and usually pre-
scribedquite freely in the elderly,on the basis of general population
trials.
Excess anticoagulation and INR variability seem to be, more
than anything, the main risk factors for bleeding in all patients
(Ansell et al., 2008). These may be prevented in the elderly with
a lower warfarin starting dose (4mg), more frequent INR mon-
itoring (with a maximum interval of 3 weeks), longer intervals
between two dose adjustments (at least 4 days apart, especially
with higher doses), and, if necessary, stricter or even 1mg step
dose adjustments, as shown in computer-assisted warfarin man-
agement systems (Harrison et al., 1997; Gage et al., 2000; Ansell
et al., 2008; Gouin-Thibault et al., 2010). The American Geri-
atrics Society recommends daily INR testing until stable, followed
by two to three times/week testing for 1–2weeks, weekly testing
for 1month, and monthly testing thereafter (American Geriatrics
Society Clinical Practice Committee, 2002). Lower intensity anti-
coagulation regimens, which have included the elderly, with target
INRs <2, can provide the same prevention efﬁcacy than stan-
dard intensity treatments, with signiﬁcantly lower bleeding risk
(Yamaguchi, 2000; Pengo et al., 2010).
Table 2 | Anticoagulation (warfarin) vs. antiplatelet therapy (aspirin)
for stroke prevention in atrial fibrillation in the elderly49, 50.
Warfarin (INR 2.0–3.0) Aspirin
Major extracranial
hemorrhage (%)
1.4/year (Mant et al., 2007) 1.6/year (Mant et al.,
2007)
Adverse events (%) 6 (Rash et al., 2007) 33 (Rash et al., 2007)
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Dabigatran etexilate, approved by the FDA in October 2010
for stroke prevention in AF, inhibits coagulation by speciﬁcally
and reversibly binding thrombin (Hussar and Zimmerman, 2011).
At a dose of 110mg twice daily, it showed similar embolic
stroke and systemic embolism rates (non-inferior p< 0.001), but
signiﬁcantly lower major bleeding rates than warfarin in a large
trial (Connolly et al., 2009). However, in patients ≥75 years,
intracranial bleeding risk was lower but extracranial bleeding risk
was similar or higher with dabigatran (Eikelboom et al., 2011).
Apixaban, a novel oral direct factor Xa inhibitor, at a dose of 5mg
twice daily compared to warfarin (at a target INR of 2.0–3.0), was
superior in preventing stroke or systemic embolism (p< 0.001
for non-inferiority, p = 0.01 for superiority), caused less bleeding
(p< 0.001), and resulted in lower mortality (p = 0.047), in a study
of 18201 patients with amean age of 70 years, of which>31%were
at least 75, a welcome older stroke risk population trial (Granger
et al., 2011). Rivaroxaban, another oral factor Xa inhibitor, was
approved by the FDA in November 2011. At a daily dose of 20mg,
vs. dose-adjusted warfarin, it was non-inferior to warfarin for
the prevention of stroke or systemic embolism (p< 0.001), and
showed less intracranial and fatal bleeding (p = 0.003), but no
difference in the risk of major bleeding (Patel et al., 2011), in a
population of patients with a mean age of 73 years. While with
these newer direct inhibitors we may be at the brink of a break-
through allowing us, at long last, to forget about INRs, it is still
uncertain whether these agents will truly result in a lower hem-
orrhagic risk in everyday practice. Other compounds are under
investigation.
Finally, validated risk stratiﬁcation schemes for better decision-
making are other useful tools to minimize bleeding risk. For
instance, the validated CHADS2 score allocates points to the pres-
ence of ﬁve clinical risk factors: congestive heart failure, hyperten-
sion, age >75 years, diabetes mellitus (1 point each), and prior
stroke/TIA (2 points; Gage et al., 2001). For patients with a
CHADS2 score of 0 (annual stroke risk 1%), the absolute ben-
eﬁt of warfarin is not substantially greater than that of aspirin.
For patients with a CHADS2 score of 2 or more (annual stroke
risk 4%), warfarin is both beneﬁcial and cost-effective. Patients
with a CHADS2 score of 1 may have a choice of either, but most
AF patients over 75 have a CHADS2 score of 2 or higher, and are
therefore appropriate candidates for warfarin (Gage et al., 2004).
The HAS–BLED score (uncontrolled Hypertension,Abnormal
renal/liver function, Stroke, Bleeding history or predisposition,
Labile INR,E lderly over 65 years, concomitantDrugs/alcohol) tar-
gets AF patients under anticoagulation. One point is given for each
risk factor, with a maximum of 9. A score of 3 or more suggests
high risk bleeding (Lip et al., 2011).
It is clear that to avoid both embolic stroke and bleeding risk in
elderly AF patients, the choice of antithrombotic drug, dosage,
treatment regimen, and appropriate evaluation of cost/beneﬁt
should be carefully tailored to the speciﬁc characteristics of this
age group.
HYPERTENSION AND ANTIHYPERTENSIVE TREATMENT
Arterial hypertension is recognized as one of the most prevalent
modiﬁable stroke risk factors. Several trials have shown the beneﬁt
of antihypertensive drugs for primary and secondary stroke pre-
vention in the general population. Some of these trials or meta
analyses have shown similar results in primary prevention in the
elderly (Gueyfﬁer et al., 1999; Beckett et al., 2008), but there are not
enough data on secondary stroke prevention. In one of the elderly
targeted trials of hypertension treatment, only 7% of participants
had a history of previous stroke (Gueyfﬁer et al., 1999). The heart
outcomes prevention evaluation (HOPE) trial included about 11%
stroke survivors, but patients beyond 80 were excluded (Bosch
et al., 2002). In the study on cognition and prognosis in the elderly
(SCOPE), a trial involving almost 5000 elderly patients, only 4%
had had a prior stroke (Lithell et al., 2003). Secondary preven-
tion stroke trials, such as PROGRESS, PATS, and MOSES were
not speciﬁcally addressed to the elderly, and the mean age of the
populations studied was <70 (PATS Collaborating Group, 1995;
PROGRESS Collaborative Group, 2001; Schrader et al., 2005).
Antihypertensives would probably beneﬁt 80-plus stroke patients
as well, but aren’t there any risks in lowering the blood pressure
in the elderly? Is not cerebral blood ﬂow compromised as a conse-
quence? In one meta analysis addressing antihypertensives in old
people, no treatment beneﬁt was seen for cardiovascular death,
and there was a non-signiﬁcant 6% relative excess death from all
causes (Gage et al., 2004). How can this be explained? Shouldn’t
such a result be investigated further?
DIABETES, CHOLESTEROL, AND LIPID-LOWERING TREATMENTS
Although diabetes is considered a stroke risk factor in the elderly,
intensive HbA1c-lowering treatment (<6.5%) has been discour-
aged by the American Heart – American Stroke Association guide-
lines because of the higher death risks involved, a recommendation
issued on the basis of data obtained from general and not from
advanced age populations (Action to Control Cardiovascular Risk
in Diabetes Study Group et al., 2008; Furie et al., 2011).
Epidemiological studies demonstrate a relationship between
high cholesterol and vascular disease in the elderly (Prospective
Studies Collaboration, 2007), and the beneﬁt of statins in prevent-
ing vascular disease and stroke, despite the lack of association of
cholesterol levels with ischemic stroke risk (Cholesterol Treatment
Triallists’ Collaboration, 2005). Again most of the evidence on
statin efﬁcacy in primary and secondary stroke prevention comes
from subgroup analyses from general population trials, despite a
large study reporting a 25% relative risk reduction in secondary
stroke (Aﬁlalo et al., 2008). There is only one secondary prevention
trial with stroke as a primary end-point, but with very few patients
over 80 (The Stroke Prevention by Aggressive Reduction in Cho-
lesterol Levels Investigators, 2006). So even when the available
evidence supports statins as effective in primary and secondary
vascular prevention in the very old, the data are just not enough
to make evidence-based decisions in stroke patients.
In summary, present available evidence shows that some stroke
management schemes may reasonably be applied to the elderly as
safely as to the population at large, but not others. Emerging data
suggest that, because the risk/beneﬁt ratio is still uncertain, stroke
management in old patients should be addressed separately. Better
evidence could help the elderly, the population at highest stroke
risk, prevent the devastating consequences of stroke.
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